Clotrimazole Lozenge

Pronunciation

Dosage Form: troche, lozenge

Clotrimazole Lozenge
(Clotrimazole Troche)

FOR TOPICAL ORAL ADMINISTRATION

Clotrimazole Lozenge Description

Each Clotrimazole Lozenge contains 10 mg clotrimazole [1-(o-chloro-α, α-diphenylbenzyl) imidazole], a synthetic antifungal agent, for topical use in the mouth.

Structural Formula:

Slideshow: Worried About Ebola? You’re More Likely to Get These 10 Serious Infections

Chemical Formula:

C22H17ClN2

The lozenge dosage form is a large, slowly dissolving tablet (troche) containing 10 mg of clotrimazole dispersed in dextrose, microcrystalline cellulose, povidone, and magnesium stearate.

Clotrimazole Lozenge - Clinical Pharmacology

Clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. The action of clotrimazole is fungistatic at concentrations of drug up to 20 mcg/mL and may be fungicidal in vitro against Candida albicans and other species of the genus Candida at higher concentrations. No single-step or multiple-step resistance to clotrimazole has developed during successive passages of Candida albicans in the laboratory; however, individual organism tolerance has been observed during successive passages in the laboratory. Such in vitro tolerance has resolved once the organism has been removed from the antifungal environment.

After oral administration of a 10 mg Clotrimazole Lozenge to healthy volunteers, concentrations sufficient to inhibit most species of Candida persist in saliva for up to three hours following the approximately 30 minutes needed for a lozenge to dissolve. The long term persistence of drug in saliva appears to be related to the slow release of clotrimazole from the oral mucosa to which the drug is apparently bound. Repetitive dosing at three hour intervals maintains salivary levels above the minimum inhibitory concentrations of most strains of Candida; however, the relationship between in vitro susceptibility of pathogenic fungi to clotrimazole and prophylaxis or cure of infections in humans has not been established.

In another study, the mean serum concentrations were 4.98 ± 3.7 and 3.23 ± 1.4 nanograms/mL of clotrimazole at 30 and 60 minutes, respectively, after administration as a lozenge.

Indications and Usage for Clotrimazole Lozenge

Clotrimazole Lozenges are indicated for the local treatment of oropharyngeal candidiasis. The diagnoses should be confirmed by a KOH smear and/or culture prior to treatment.

Clotrimazole Lozenges are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION.)

Contraindications

Clotrimazole Lozenges are contraindicated in patients who are hypersensitive to any of its components.

Warning

Clotrimazole Lozenges are not indicated for the treatment of systemic mycoses including systemic candidiasis.

Precautions

Abnormal liver function tests have been reported in patients treated with Clotrimazole Lozenges; elevated SGOT levels were reported in about 15% of patients in the clinical trials. In most cases the elevations were minimal and it was often impossible to distinguish effects of clotrimazole from those of other therapy and the underlying disease (malignancy in most cases). Periodic assessment of hepatic function is advisable particularly in patients with pre-existing hepatic impairment.

Since patients must be instructed to allow each lozenge to dissolve slowly in the mouth in order to achieve maximum effect of the medication, they must be of such an age and physical and/or mental condition to comprehend such instructions.

Carcinogenesis:

An 18 month dosing study with clotrimazole in rats has not revealed any carcinogenic effect.

Usage in Pregnancy:

Pregnancy Category C:

Clotrimazole has been shown to be embryotoxic in rats and mice when given in doses 100 times the adult human dose (in mg/kg), possibly secondary to maternal toxicity. The drug was not teratogenic in mice, rabbits, and rats when given in doses up to 200, 180, and 100 times the human dose.

Clotrimazole given orally to mice from nine weeks before mating through weaning at a dose 120 times the human dose was associated with impairment of mating, decreased number of viable young, and decreased survival to weaning. No effects were observed at 60 times the human dose. When the drug was given to rats during a similar time period at 50 times the human dose, there was a slight decrease in the number of pups per litter and decreased pup viability.

There are no adequate and well controlled studies in pregnant women. Clotrimazole Lozenges should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

Safety and effectiveness of clotrimazole in children below the age of 3 years have not been established; therefore, its use in such patients is not recommended.

The safety and efficacy of the prophylactic use of Clotrimazole Lozenges in children have not been established.

GERIATRIC USE

Clinical studies of clotrimazole did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Adverse Reactions

Abnormal liver function tests have been reported in patients treated with Clotrimazole Lozenges; elevated SGOT levels were reported in about 15% of patients in the clinical trials (See Precautions section).

Nausea, vomiting, unpleasant mouth sensations and pruritus have also been reported with the use of the lozenge.

Overdosage

No data available.

Drug Abuse and Dependence

No data available.

Clotrimazole Lozenge Dosage and Administration

Clotrimazole Lozenges must be slowly dissolved in the mouth. The recommended dose is one lozenge five times a day for fourteen consecutive days. Only limited data are available on the safety and effectiveness of the Clotrimazole Lozenge after prolonged administration; therefore, therapy should be limited to short term use, if possible.

For prophylaxis to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation, the recommended dose is one lozenge three times daily for the duration of chemotherapy or until steroids are reduced to maintenance levels.

How is Clotrimazole Lozenge Supplied

Clotrimazole Lozenges, 10 mg, white discoid, uncoated tablets, debossed with "PAD" over "0107" on one side and plain on the other, are supplied as follows:

Strength NDC Code Lozenge Identification

Bottles of 70:

10 mg

0574-0107-70

PAD 0107

Bottles of 140:

10 mg

0574-0107-14

PAD 0107

Boxes of 70 foil packs:

10 mg

0574-0107-77

PAD 0107

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]

Avoid freezing.

Rx Only

Manufactured By

Perrigo®

Minneapolis, MN 55427
2200403

(03-12)

PRINCIPAL DISPLAY PANEL

Rx Only

NDC 0574-0107-70

ClotrimazoleLozenge
(Clotrimazole Troche)

10 mg

DESCRIPTION: Each lozenge contains

10 mg of clotrimazole,

[1-(o-chloro-α, α-diphenylbenzyl) imidazole]

DOSAGE: Each lozenge must be dissolved slowly in the mouth

See accompanying literature for complete information

Dispense in tight containers (USP)

Store at 20° to 25°C (68° to 77°F)

[see USP Controlled Room Temperature]

Avoid Freezing.

70 Lozenges

Perrigo®

CLOTRIMAZOLE 
Clotrimazole Lozenge
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0574-0107
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CLOTRIMAZOLE (CLOTRIMAZOLE) CLOTRIMAZOLE 10 mg
Inactive Ingredients
Ingredient Name Strength
DEXTROSE  
CELLULOSE, MICROCRYSTALLINE  
POVIDONES  
MAGNESIUM STEARATE  
Product Characteristics
Color WHITE Score no score
Shape ROUND Size 16mm
Flavor Imprint Code PAD;0107
Contains         
Packaging
# Item Code Package Description
1 NDC:0574-0107-70 70 LOZENGE in 1 BOTTLE, PLASTIC
2 NDC:0574-0107-14 140 LOZENGE in 1 BOTTLE, PLASTIC
3 NDC:0574-0107-77 70 PACKET in 1 BOX
3 1 LOZENGE in 1 PACKET
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA076763 12/01/2005
Labeler - Paddock Laboratories, LLC (967694121)
Revised: 11/2013
 
Paddock Laboratories, LLC
Hide
(web5)